{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-21-029173","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2021-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:15.374429+00:00","generated_at":"2026-06-27T22:45:02.969949+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Mesa Labs announces new segment reporting structure effective Q3 FY2022","bullets":["Four new segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, Calibration Solutions.","Clinical Genomics segment consists of recently acquired Agena Bioscience business.","Calibration Solutions combines former Instruments and Continuous Monitoring segments.","Over 90% of future revenues expected from pharma, medical device, and healthcare verticals.","Change reflects management's focus on higher-growth Life Sciences Tools applications."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-21-029173","json":"https://secwatch.observer/filing/0001437749-21-029173.json","markdown":"https://secwatch.observer/filing/0001437749-21-029173.md","text":"https://secwatch.observer/filing/0001437749-21-029173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/0001437749-21-029173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774921029173/mlab20211221_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T22:45:02.969949+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}